Artivion, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Artivion, Inc. - overview
Established
1984
Location
Kennesaw, GA, US
Primary Industry
Medical Devices & Equipment
About
Based in Georgia, US, and founded in 1984 and led by CEO J. Patrick Mackin, Artivion, formerly known as CryoLife, Inc. , operates as a distributor of medical devices and implantable human tissues used in cardiac and vascular surgical procedures focused on aortic repair. In January 2024, Ares Management provided USD 350 million senior secured credit facilities, which is comprised of a USD 190 million term loan, a USD 60 million revolving credit facility, and an additional USD 100 million delayed draw term loan, to support the growth of Artivion.
Artivion manufacturers a variety of devices designed for different aortic and cardiac applications such as On-X Aortic and Mitral Heart Valves, AMDS Hybrid Prosthesis, and E-VITA Open NEO Hybrid Stent Graft System. The company offers surgical sealants and ancillary solutions like the BIOGLUE Surgical Adhesive and PHOTOFIX Decellularized Bovine Pericardium.
Current Investors
Wells Fargo Capital Finance, GE Healthcare Financial Services, U.S. Department of Defense
Primary Industry
Medical Devices & Equipment
Sub Industries
Surgical Devices, Medical Equipment Distributors, Biomaterials
Website
www.artivion.com
Verticals
HealthTech, Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Artivion, Inc. - timeline of key events
Artivion, Inc. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 119,626,000 | 131,718,000 | 140,763,000 | 144,641,000 | 145,898,000 | 180,380,000 | 189,702,000 | 262,841,000 | 276,222,000 | 253,227,000 | 298,836,000 | 313,789,000 | - | - | - |
| % Revenue Growth (YoY) | - | 10.1% | 6.9% | 2.8% | 0.9% | 23.6% | 5.2% | 38.6% | 5.1% | (8.3%) | 18.0% | 5.0% | - | - | - |
| EBITDA (USD) | 16,603,000 | 18,245,000 | 19,663,000 | 14,866,000 | 11,217,000 | 30,204,000 | 17,715,000 | 27,407,000 | 35,359,000 | 23,153,000 | 32,094,000 | 28,643,000 | - | - | - |
| Operating Income (USD) | 11,643,000 | 12,612,000 | 13,820,000 | 8,838,000 | 5,354,000 | 21,820,000 | 7,970,000 | 9,312,000 | 17,042,000 | 2,441,000 | 8,117,000 | 6,201,000 | - | - | - |
| Operating Margin | 9.7% | 9.6% | 9.8% | 6.1% | 3.7% | 12.1% | 4.2% | 3.5% | 6.2% | 1.0% | 2.7% | 2.0% | - | - | - |
| % EBITDA Margin | 13.9% | 13.9% | 14.0% | 10.3% | 7.7% | 16.7% | 9.3% | 10.4% | 12.8% | 9.1% | 10.7% | 9.1% | - | - | - |
| NET Income (USD) | 7,371,000 | 7,946,000 | 16,172,000 | 7,322,000 | 4,005,000 | 10,778,000 | 3,704,000 | (2,840,000) | 1,720,000 | (16,682,000) | (14,834,000) | (19,192,000) | - | - | - |
| % Net Margin | 6.2% | 6.0% | 11.5% | 5.1% | 2.7% | 6.0% | 2.0% | (1.1%) | 0.6% | (6.6%) | (5.0%) | (6.1%) | - | - | - |
Artivion, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Completed | Artivion, Inc. | - |
Displaying 1 - 1 of 1
Artivion, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.